An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
NCT05454488
Recruiting
To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
NCT05593523
Recruiting
This study investigates fluorescence image-guided surgery to allow precise identification of necrotic tissue both preoperatively and intraoperatively in burn patients. Furthermore, it uses a multi-model approach to elucidate the localization of ICG in inflammation and necrosis to determine how this novel use of a well-known fluorescence marker can be optimized to aid in surgical decision making. This proposal will provide the necessary data to support the design of a larger clinical trial to stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Burn Wound
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +53 locations
Conditions: Prostate Cancer
Register for Updates
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756
Recruiting
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarctio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Advanced Cardiovascular - Alexander City ( Site 0156), Alexander City, Alabama +662 locations
Conditions: Arteriosclerosis, Hypercholesterolaemia
Register for Updates
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
NCT06124196
Recruiting
Duchenne muscular dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in DMD, but substantial knowledge gaps exist regarding predisposing risk factors. In the general population, hyperglycemia, insulin resistance, and decreased heart rate variability (HRV; reflecting autonomic dysfunction) are associated with cardiomyopathy (CM). It is unclear whether these factors are associated with DMD-CM.... Read More
Gender:
MALE
Ages:
10 years and above
Trial Updated:
04/21/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764
Recruiting
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/21/2025
Locations: Stanford Neuromuscular Research, San Carlos, California +25 locations
Conditions: Myotonic Dystrophy Type 1 (DM1)
Register for Updates
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
NCT06305728
Recruiting
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +7 locations
Conditions: Pancreatic Cyst
Register for Updates
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291
Recruiting
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama +221 locations
Conditions: Hypercholesterolemia
Register for Updates
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324
Recruiting
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Urology Centers of Alabama, Homewood, Alabama +159 locations
Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Register for Updates
TNBC Gut Microbiota During Neoadjuvant Treatment
NCT06610097
Recruiting
The gut microbiome is made up of the microbes (such as bacteria, viruses, and other organisms too small to see with the naked eye) that live in the digestive tract and has been shown to be important in metabolizing food, extracting vitamins and nutrients from food, and maintaining a healthy gut lining. The gut microbiome plays an important role in overall health and has been shown to dynamically change in response to early-stage triple-negative breast cancer-directed therapies, which in turn has... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Scripps Clinic, La Jolla, California
Conditions: Breast Cancer, Triple Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Treatments for Improving Mood in Women Survivors of Interpersonal Violence: A Community-Engaged Study-1.2
NCT06657950
Recruiting
Phase 1.2: Open Trial N=15 women survivors of interpersonal violence will be enrolled into a single-arm pilot trial to test the adapted integrative hatha yoga and mindful self-compassion program.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
04/21/2025
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Distress
Register for Updates
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT06704191
Recruiting
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Non-Muscle Invasive Bladder Carcinoma, Stage I Bladder Cancer AJCC V8, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Register for Updates